Scottsdale, AZ 4/24/2012 1:40:00 AM
News / Finance

BioTime (BTX) and Subsidiary LifeMap Sciences Ink Agreement to Acquire XenneX

QualityStocks would like to highlight BioTime (NYSE AMEX:BTX), a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications. BioTime develops and markets research products in the field of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate(TM) cell lines, culture media, and differentiation kits.

In the company’s news last week,

BioTime announced that the company, along with its wholly owned subsidiary LifeMap Sciences, has signed a definitive agreement to acquire XenneX through a merger of XenneX into LifeMap. The deal is expected to close within 30 days.

XenneX provides biotech, pharmaceutical, and life sciences companies with services and tools to enhance their bio-medical research. The company holds the exclusive, worldwide licenses to market GeneCards®, a searchable, integrated database of human genes; and PanDaTox, a recently developed, searchable database that can be used to identify genes and intergenic regions that are unclonable in E. coli, to aid in the discovery of new antibiotics and biotechnologically beneficial functional genes.

BioTime said that future plans include making LifeMap the principal marketing subsidiary for BioTime research products, as well as to utilize LifeMap’s databases as part of its online marketing strategy.  

In addition, BioTime will collaborate with LifeMap scientists to utilize LifeMap’s proprietary discovery platform, stem cell database, and the newly acquired database products to aid in the development of BioTime’s proprietary ACTCellerate™.

Per the agreement, XenneX stockholders will receive approximately 1,362,589 shares of LifeMap common stock, approximately 13 percent of the LifeMap common stock outstanding upon the closing of the transaction; XenneX shareholders will also receive approximately 448,430 BioTime common shares.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.